By adding PD-1 immune checkpoint inhibitor with MEK inhibitors gives rise to the most powerful tumor regression in the rodents.
Lung cancer is one of the most severe diseases in the world, affecting both men and women. Every year, there will be around 228,000 new lung cancer cases around the world. In fact, 30% of them will have mutations in the KRAS pathway. This type of mutation complicates cancer, which is more aggressive and difficult to treat. A new study was published in ‘Cancer Research’, where the team discovered a new treatment approach that will help the group of patients recover from this life-threatening disease. KRAS gene mutation regulates the cell signaling in ‘on’ and ‘off’ mode, which leads to cell growth and division.
During the study, researchers identified the MEK inhibitors increase the number of receptors on the cell surface for TNFα, which leads to the delivery of more sustained and potent cell death signals. Moreover, MEK inhibits are increases expression of TNFα and IFNγ target genes significantly, which leads to anti-tumor immunity. Researchers discovered that by adding PD-1 immune checkpoint inhibitor with MEK inhibitors gives rise to the most powerful tumor regression in the rodents.
Now, the researchers are planning for further studies MEK inhibitors with other immune therapies, which will offer the strong expression of these cytokines in the tumor microenvironment. For instance, adoptive T cell therapy and CAR T therapy approaches. Amer Beg, lead author of the study said, “Demonstrating that an anti-cancer agent can so effectively modulate the activity of a cytokine signaling pathway crucial for so many biological processes is conceptually novel and can lead to a new understanding of oncogenic pathways and strategies for targeting them”